DK, R., & N, G. (2026). Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: An editorial on the phase 3 SYMPATICO trial. AME clinical trials review, 4, . https://doi.org/10.21037/actr-25-72
Chicago Style (17th ed.) CitationDK, Reef, and Grover N. "Ibrutinib Plus Venetoclax for Patients with Relapsed or Refractory Mantle Cell Lymphoma: An Editorial on the Phase 3 SYMPATICO Trial." AME Clinical Trials Review 4 (2026). https://doi.org/10.21037/actr-25-72.
MLA (9th ed.) CitationDK, Reef, and Grover N. "Ibrutinib Plus Venetoclax for Patients with Relapsed or Refractory Mantle Cell Lymphoma: An Editorial on the Phase 3 SYMPATICO Trial." AME Clinical Trials Review, vol. 4, 2026, https://doi.org/10.21037/actr-25-72.
Warning: These citations may not always be 100% accurate.
